Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 364 clinical trials
featured
Co-Infusion of Umbilical Cord Blood and Haploidentical CD34+ Cells Following Nonmyeloablative Conditioning as Treatment for Severe Aplastic Anemia and MDS Associated with Severe Neutropenia Refractory to Immunosuppressive Therapy

This study will evaluate the safety and effectiveness of treating patients with severe aplastic anemia (SAA) or myelopdysplastic syndrome (MDS) with both peripheral blood stem cells from a family member and umbilical cord blood stem cells from an unrelated donor. Patients with SAA or MDS for whom other treatments have …

myelodysplastic syndromes
aplastic anemia
anemia studies
myelodysplastic syndrome (mds)
anemia
  • 48 views
  • 22 Dec, 2020
  • 1 location
featured
A Randomized Trial of Sirolimus (Rapamune) for Relapse Prevention in Patients with Severe Aplastic Anemia Responsive to Immunosuppressive Therapy

Background: People with severe aplastic anemia (SAA) do not make enough red and white blood cells, and/or platelets. Their body's immune system stops the bone marrow from making these cells. The treatment cyclosporine leads to better blood counts. But when this treatment is stopped, the disease may return in 1 …

myelodysplastic syndromes
aplastic anemia
anemia studies
myelodysplastic syndrome (mds)
anemia
  • 61 views
  • 22 Dec, 2020
  • 1 location
featured
Haplo-identical Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using Peripheral Blood Stem Cells and Post-Transplant Cyclophosphamide for GVHD Prophylaxis

Background: Severe aplastic anemia (SAA) and myelodysplastic syndrome (MD) cause serious blood problems. Stem cell transplants using bone marrow or blood plus chemotherapy can help. Researchers want to see if using peripheral blood stem cells (PBSCs) rather than bone marrow cells works too. PBSCs are easier to collect and have …

myelodysplastic syndromes
aplastic anemia
anemia studies
myelodysplastic syndrome (mds)
anemia
  • 57 views
  • 22 Dec, 2020
  • 1 location
featured
Celgene MDS-AML Registry Connect

Celgene MDS-AML Registry Connect

  • 38 views
  • 08 Nov, 2020
  • 1 location
Flotetuzumab for Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Following Allogeneic Hematopoietic Cell Transplantation (Allo-HCT)

The investigators hypothesize that MGD006 for relapsed AML following allo-HCT will be safe, tolerable and may facilitate preferential immune effector cell retargeting of leukemic cells resulting in improved patient outcomes. Furthermore, administration of a donor lymphocyte infusion (DLI) (if available) in combination with MGD006 will be safe, tolerable and may …

  • 0 views
  • 31 May, 2021
  • 1 location
A Study of Evorpacept (ALX148) With Azacitidine for Higher Risk Myelodysplastic Syndrome (ASPEN-02)

This Phase 1/2 clinical study will evaluate evorpacept (ALX148) in combination with azacitidine for the treatment of patients with higher risk myelodysplastic syndrome (MDS).

  • 0 views
  • 03 Sep, 2021
  • 6 locations
A Study to Determine the Absolute Oral Bioavailability of Quizartinib Using a Radiolabeled Microtracer in Healthy Subjects

Quizartinib, a selective FLT3 inhibitor, is being developed as a treatment for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The absolute oral bioavailability of quizartinib

  • 0 views
  • 08 Jul, 2021
  • 1 location
Allogeneic HSCT in MDS Patients Based on Risk According to R-IPSS

patients affected by Myelodysplastic Syndrome (MDS), according to IPSS-R.

  • 0 views
  • 27 Mar, 2021
  • 1 location
Safety of SP-420 in the Treatment of Transfusional Iron Overload

This study enrolls patients with myelodysplastic syndrome (MDS) and myelofibrosis (MFS), with transfusional iron overload and treats them with the investigational iron chelator, SP-420. SP-420

oophorectomy
serum ferritin level
packed red blood cells
chelation therapy
chelators
  • 0 views
  • 03 Jul, 2021
  • 1 location
Unrelated Donor Transplant Versus Immune Therapy in Pediatric Severe Aplastic Anemia

The purpose of this study is to determine the feasibility of comparing outcomes of patients treated de novo with immunosuppressive therapy (IST) versus matched unrelated donor (MUD) hematopoietic stem cell transplant (HSCT) for pediatric acquired severe aplastic anemia.

neutrophil count
cyclosporine
hla-a
immunosuppression
aplastic anemia
  • 28 views
  • 08 Aug, 2021
  • 13 locations